Alzamend Neuro (ALZN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALZN Alzamend Neuro

Watchlist

1.1900
0.00000.00%

Close Dec 13 16:00 ET

6.47MMarket Cap-0.20P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Alzamend Neuro | 8-K: Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
SECDec 12 16:37 ET · Announcements
Alzamend Neuro Says Net Cash Gained by Financing Activity $8.3M
TipRanksDec 12 08:15 ET
Express News | Alzamend Neuro Q2 EPS $(0.40) Beats $(0.77) Estimate
BenzingaDec 12 08:03 ET
Press Release: Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Dow JonesDec 12 08:00 ET
Alzamend Neuro | 10-Q: Q2 2025 Earnings Report
SECDec 11 16:36 ET · Announcements
Express News | Alzamend Neuro Inc: Both Treatments Had No Negative Impact on Mice's Body Weight or Clinical Signs During Treatment Period
ReutersNov 19 08:03 ET

Comments

Jaguar8

Dec 12 07:05

NEWS ER

$Alzamend Neuro (ALZN.US)$
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Thursday, 12th December at 8:00 am
• During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million
• Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash
• Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025
Alzamend Neuro, Inc. (NASDAQ: ALZN) ("...

Teo knows

Dec 11 15:56

$Alzamend Neuro (ALZN.US)$ this grabge should move its horrible

Trytosaveabit

Oct 16 06:41

A Bit More

$Alzamend Neuro (ALZN.US)$ Alzamend Neuro Tells Benzinga 'Data Confirm the Positive Topline Results Announced in June 2023 Identifying a Maximum Tolerated Dose as Assessed by an Independent Safety Review Committee'!
Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'

Trytosaveabit

Oct 16 06:32

News

$Alzamend Neuro (ALZN.US)$ EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
Benzinga· just
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023.
Identified by an independent safety review committee, this MTD represents a pivotal ...

frogoracletrading

Aug 31 12:21

$ALZN Support / Resistance Levels

Worth keeping an eye on for a bounce next week. If the top of the GAP holds 2.22 then look for a move to test 2.98 and beyond.
Larger Image: tradingview.com...
$Alzamend Neuro (ALZN.US)$

Trending US Stocks

Symbol Mini Chart % Chg

Unlock the Full List